G1 Therapeutics, Inc. Common Stock
GTHX
GTHX was delisted on the 17th of September, 2024.
116 hedge funds and large institutions have $123M invested in G1 Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 32 increasing their positions, 30 reducing their positions, and 24 closing their positions.
61% more call options, than puts
Call options by funds: $550K | Put options by funds: $341K
50% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 24
12% more funds holding
Funds holding: 104 → 116 (+12)
7% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 30
57% less capital invested
Capital invested by funds: $287M → $123M (-$164M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$6.3M |
| 2 |
Renaissance Technologies
New York
|
+$4.56M |
| 3 |
Millennium Management
New York
|
+$4.18M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$3.04M |
| 5 |
D.E. Shaw & Co
New York
|
+$2.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$12.1M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
-$11M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.32M |
| 4 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$3.11M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
-$2.79M |
GTHX Hedge Fund Activity: Q4 2022 in Review
116 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q4 2022, worth a combined $123M — down 57% from $287M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new GTHX positions and 24 closed out — a net gain of 12 holders — while 32 added to existing stakes and 30 trimmed.
The largest buyer was Woodline Partners, adding an estimated $6.3M. The largest seller was State Street, cutting an estimated $12.1M.
- 116 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q4 2022, up from 104 in Q3 2022.
- Funds reported $123M of G1 Therapeutics, Inc. Common Stock stock for Q4 2022, down 57% quarter-over-quarter.
- 36 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q4 2022 and 24 closed out, a net change of +12 holders.
- The largest G1 Therapeutics, Inc. Common Stock buyer in Q4 2022 was Woodline Partners, an estimated $6.3M added.
- The largest G1 Therapeutics, Inc. Common Stock seller in Q4 2022 was State Street, an estimated $12.1M sold.
Based on aggregated 13F filings for Q4 2022.